FGFR1 and chronic myelogenous leukemia, BCR-ABL1 positive: AP24534 (Ponatinib) is a pan BCR–ABL, including BCR–ABLT315I, inhibitor used in the clinic to treat chronic myeloid leukaemia; however, AP24534 exhibits inhibitory activity towards VEGFR-2, FGFR-1 (fibroblast growth factor receptor-1), scr and Lyn (protein tyrosine kinase Lyn) kinases as well [97].